Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ocular Therapeutix (OCUL) Free Cash Flow (2016 - 2025)

Historic Free Cash Flow for Ocular Therapeutix (OCUL) over the last 13 years, with Q4 2025 value amounting to -$57.1 million.

  • Ocular Therapeutix's Free Cash Flow fell 4404.89% to -$57.1 million in Q4 2025 from the same period last year, while for Dec 2025 it was -$216.9 million, marking a year-over-year decrease of 5952.12%. This contributed to the annual value of -$216.9 million for FY2025, which is 5952.12% down from last year.
  • Latest data reveals that Ocular Therapeutix reported Free Cash Flow of -$57.1 million as of Q4 2025, which was down 4404.89% from -$56.7 million recorded in Q3 2025.
  • Ocular Therapeutix's Free Cash Flow's 5-year high stood at -$8.0 million during Q3 2023, with a 5-year trough of -$57.1 million in Q4 2025.
  • Over the past 5 years, Ocular Therapeutix's median Free Cash Flow value was -$22.5 million (recorded in 2023), while the average stood at -$28.0 million.
  • In the last 5 years, Ocular Therapeutix's Free Cash Flow soared by 4366.61% in 2022 and then tumbled by 35861.59% in 2024.
  • Over the past 5 years, Ocular Therapeutix's Free Cash Flow (Quarter) stood at -$15.8 million in 2021, then fell by 21.06% to -$19.1 million in 2022, then fell by 19.91% to -$22.9 million in 2023, then plummeted by 72.96% to -$39.6 million in 2024, then crashed by 44.05% to -$57.1 million in 2025.
  • Its Free Cash Flow stands at -$57.1 million for Q4 2025, versus -$56.7 million for Q3 2025 and -$56.5 million for Q2 2025.